Tackling Cancer Stem Cells via Inhibition of EMT Transcription Factors

Stem Cells International

Volumn 2016, Issue , 2016, Pages

  Mladinich, Megan ^a   Ruan, Diane ^a,b   Chan, Chia Hsin ^a,b  

^a STONY BROOK UNIVERSITY   (United States)

^b Stony Brook Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST;

CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STEM CELL; CELL DIFFERENTIATION; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; LIVER CANCER; MOLECULAR GENETICS; MULTIPLE MYELOMA; NONHUMAN; NUCLEAR REPROGRAMMING; PHENOTYPE; PROTEIN PROCESSING; REVIEW; RNAI THERAPEUTICS; TARGET CELL DESTRUCTION; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; UPREGULATION;

EID: 84994438774     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2016/5285892     Document Type: Review

References (123)

1. V. J. Findlay, C. Wang, D. K. Watson, and E. R. Camp, "Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer," Cancer Gene Therapy, vol. 21, no. 5, pp. 181-187, 2014.
2. L. Vermeulen, M. Todaro, F. De Sousa Mello et al., "Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 36, pp. 13427-13432, 2008.
3. S. A. Mani, W. Guo, M.-J. Liao et al., "The epithelial-mesenchymal transition generates cells with properties of stemcells," Cell, vol. 133, no. 4, pp. 704-715, 2008.
4. S. H. Sahlberg, D. Spiegelberg, B. Glimelius, B. Stenerlöw, and M. Nestor, "Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cells," PLoS ONE, vol. 9, no. 4, article e94621, 2014.
5. T. Woo, K. Okudela, H. Mitsui et al., "Prognostic value of CD133 expression in stage I lung adenocarcinomas," International Journal of Clinical and Experimental Pathology, vol. 4, no. 1, pp. 32-42, 2010.
6. R. Pallini, L. Ricci-Vitiani, G. L. Banna et al., "Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme," Clinical Cancer Research, vol. 14, no. 24, pp. 8205-8212, 2008.
7. M. Shipitsin, L. L. Campbell, P. Argani et al., "Molecular definition of breast tumor heterogeneity," Cancer Cell, vol. 11, no. 3, pp. 259-273, 2007.
8. L. V. Nguyen, R. Vanner, P. Dirks, and C. J. Eaves, "Cancer stem cells: an evolving concept," Nature Reviews Cancer, vol. 12, no. 2, pp. 133-143, 2012.
9. K. Rycaj and D. G. Tang, "Cell-of-origin of cancer versus cancer stem cells: assays and interpretations," Cancer Research, vol. 75, no. 19, pp. 4003-4011, 2015.
10. D. A. Lawson, N. R. Bhakta, K. Kessenbrock et al., "Single-cell analysis reveals a stem-cell program in humanmetastatic breast cancer cells," Nature, vol. 526, no. 7571, pp. 131-135, 2015.
11. A. Kreso and J. E. Dick, "Evolution of the cancer stem cell model," Cell Stem Cell, vol. 14, no. 3, pp. 275-291, 2014.
12. P. Dalerba, T. Kalisky, D. Sahoo et al., "Single-cell dissection of transcriptional heterogeneity in human colon tumors," Nature Biotechnology, vol. 29, no. 12, pp. 1120-1127, 2011.
13. K. Ito, A. Carracedo, D. Weiss et al., "A PML-PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance," Nature Medicine, vol. 18, no. 9, pp. 1350-1358, 2012.
14. T. Suda, K. Takubo, and G. L. Semenza, "Metabolic regulation of hematopoietic stemcells in the hypoxic niche," Cell Stem Cell, vol. 9, no. 4, pp. 298-310, 2011.
15. N. A. Dallas, L. Xia, F. Fan et al., "Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition," Cancer Research, vol. 69, no. 5, pp. 1951-1957, 2009.
16. C. A. O'Brien, A. Pollett, S. Gallinger, and J. E. Dick, "A human colon cancer cell capable of initiating tumour growth in immunodeficient mice," Nature, vol. 445, no. 7123, pp. 106-110, 2007.
17. A. Kreso, C. A. O'Brien, P. Van Galen et al., "Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer," Science, vol. 339, no. 6119, pp. 543-548, 2013.
18. M. P. Ponnusamy and S. K. Batra, "Ovarian cancer: emerging concept on cancer stem cells," Journal of Ovarian Research, vol. 1, article 4, 2008.
19. M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J. Morrison, and M. F. Clarke, "Prospective identification of tumorigenic breast cancer cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 7, pp. 3983-3988, 2003.
20. W. Matsui, C. A. Huff, Q. Wang et al., "Characterization of clonogenic multiple myeloma cells," Blood, vol. 103, no. 6, pp. 2332-2336, 2004.
21. T. Lapidot, C. Sirard, J. Vormoor et al., "A cell initiating human acute myeloid leukaemia after transplantation into SCID mice," Nature, vol. 367, no. 6464, pp. 645-648, 1994.
22. D. Bonnet and J. E. Dick, "Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell," Nature Medicine, vol. 3, no. 7, pp. 730-737, 1997.
23. V. Plaks, N. Kong, and Z. Werb, "Thecancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?" Cell Stem Cell, vol. 16, no. 3, pp. 225-238, 2015.
24. H. F. Dvorak, "Tumors: wounds that do not heal: similarities between tumor stroma generation and wound healing," New England Journal of Medicine, vol. 315, no. 26, pp. 1650-1659, 1986.
25. M. J. Bissell, H. G. Hall, and G. Parry, "How does the extracellular matrix direct gene expression?" Journal of Theoretical Biology, vol. 99, no. 1, pp. 31-68, 1982.
26. X. Zheng, J. L. Carstens, J. Kim et al., "Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer," Nature, vol. 527, no. 7579, pp. 525-530, 2015.
27. R. Kalluri and R. A. Weinberg, "The basics of epithelial-mesenchymal transition," Journal of Clinical Investigation, vol. 119, no. 6, pp. 1420-1428, 2009.
28. J. P. Thiery and J. P. Sleeman, "Complex networks orchestrate epithelial-mesenchymal transitions," Nature Reviews Molecular Cell Biology, vol. 7, no. 2, pp. 131-142, 2006.
29. B. Toh, X. Wang, J. Keeble et al., "Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor," PLoS Biology, vol. 9, no. 9, Article ID e1001162, 2011.
30. A. Cano, M. A. Pérez-Moreno, I. Rodrigo et al., "The transcription factor Snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression," Nature Cell Biology, vol. 2, no. 2, pp. 76-83, 2000.
31. J. A. Efstathiou, D. Liu, J. M. D. Wheeler et al., "Mutated epithelial cadherin is associated with increased tumorigenicity and loss of adhesion and of responsiveness to the motogenic trefoil factor 2 in colon carcinoma cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 5, pp. 2316-2321, 1999.
32. C. Woischke, C. Blaj, E. M. Schmidt et al., "CYB5R1 links epithelial-mesenchymal transition and poor prognosis in colorectal cancer," Oncotarget, vol. 7, no. 21, pp. 31350-31360, 2016.
33. M. H. Jang, H. J. Kim, E. J. Kim, Y. R. Chung, and S. Y. Park, "Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome," Human Pathology, vol. 46, no. 9, pp. 1267-1274, 2015.
34. M. M. Javle, J. F. Gibbs, K. K. Iwata et al., "Epithelial-Mesenchymal Transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resectedpancreatic cancer," Annals of Surgical Oncology, vol. 14, no. 12, pp. 3527-3533, 2007.
35. M. Dima, V. Pecce, M. Biffoni et al., "Molecular profiles of cancer stem-like cell populations in aggressive thyroid cancers," Endocrine, vol. 53, no. 1, pp. 145-156, 2016.
36. L. Alonso-Alconada, L. Muinelo-Romay, K. Madissoo et al., "Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer," Molecular Cancer, vol. 13, no. 1, article 223, 2014.
37. F. Tomao, A. Papa, S. Martina et al., "Investigating molecular profiles of ovarian cancer: an update on cancer stem cells," Journal of Cancer, vol. 5, no. 5, pp. 301-310, 2014.
38. T.A. DiMeo, K. Anderson, P. Phadke et al., "Anovel lungmetastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer," Cancer Research, vol. 69, no. 13, pp. 5364-5373, 2009.
39. B. C. Fuchs, T. Fujii, J. D. Dorfman et al., "Epithelial-tomesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells," Cancer Research, vol. 68, no. 7, pp. 2391-2399, 2008.
40. K. Polyak and R. A. Weinberg, "Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits," Nature Reviews Cancer, vol. 9, no. 4, pp. 265-273, 2009.
41. I. Fabregat, A. Malfettone, and J. Soukupova, "New insights into the crossroads between EMT and stemness in the context of cancer," Journal of Clinical Medicine, vol. 5, no. 3, article 37, 2016.
42. N. McCormack and S. O'Dea, "Regulation of epithelial to mesenchymal transition by bone morphogenetic proteins," Cellular Signalling, vol. 25, no. 12, pp. 2856-2862, 2013.
43. J.-Y. Yang, C. S. Zong, W. Xia et al., "MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation," Molecular and Cellular Biology, vol. 26, no. 19, pp. 7269-7282, 2006.
44. A. Puisieux, T. Brabletz, and J. Caramel, "Oncogenic roles of EMT-inducing transcription factors," Nature Cell Biology, vol. 16, no. 6, pp. 488-494, 2014.
45. H. Zheng and Y. Kang, "Multilayer control of the EMT master regulators," Oncogene, vol. 33, no. 14, pp. 1755-1763, 2014.
46. M. Garg, "Epithelial-mesenchymal transition-activating transcription factors-multifunctional regulators in cancer," World Journal of Stem Cells, vol. 5, no. 4, pp. 188-195, 2013.
47. S. A. Mani, J. Yang, M. Brooks et al., "Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 24, pp. 10069-10074, 2007.
48. G. Z. Cheng, J. Chan, Q. Wang, W. Zhang, C. D. Sun, and L.-H. Wang, "Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel," Cancer Research, vol. 67, no. 5, pp. 1979-1987, 2007.
49. K. A. Hartwell, B. Muir, F. Reinhardt, A. E. Carpenter, D. C. Sgroi, and R. A. Weinberg, "The Spemann organizer gene, Goosecoid, promotes tumor metastasis," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 50, pp. 18969-18974, 2006.
50. S. Lamouille, J. Xu, and R. Derynck, "Molecular mechanisms of epithelial-mesenchymal transition," Nature Reviews Molecular Cell Biology, vol. 15, no. 3, pp. 178-196, 2014.
51. W. Guo, Z. Keckesova, J. L. Donaher et al., "Slug and Sox9 cooperatively determine the mammary stemcell state," Cell, vol. 148, no. 5, pp. 1015-1028, 2012.
52. J. Fu, L. Qin, T. He et al., "The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis," Cell Research, vol. 21, no. 2, pp. 275-289, 2011.
53. E. Batlle, E. Sancho, C. Franci et al., "The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells," Nature Cell Biology, vol. 2, no. 2, pp. 84-89, 2000.
54. H. Peinado, E. Ballestar, M. Esteller, and A. Cano, "Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex," Molecular and Cellular Biology, vol. 24, no. 1, pp. 306-319, 2004.
55. V. Bolós, H. Peinado, M. A. Pérez-Moreno, M. F. Fraga, M. Esteller, and A. Cano, "The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors," Journal of Cell Science, vol. 116, no. 3, pp. 499-511, 2003.
56. W. Zhou, R. Lv, W. Qi et al., "Snail contributes to the maintenance of stem cell-like phenotype cells in human pancreatic cancer," PLoS ONE, vol. 9, no. 1, article e87409, 2014.
57. Y.-N. Liu, J. J. Yin, W. Abou-Kheir et al., "MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slugindependent mechanisms," Oncogene, vol. 32, no. 3, pp. 296-306, 2013.
58. T. A. Proia, P. J. Keller, P. B. Gupta et al., "Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate," Cell Stem Cell, vol. 8, no. 2, pp. 149-163, 2011.
59. N.K. Kurrey, S. P. Jalgaonkar, A.V. Joglekar et al., "Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells," Stem Cells, vol. 27, no. 9, pp. 2059-2068, 2009.
60. J. Yang, S. A. Mani, J.L. Donaher et al., "Twist, amaster regulator of morphogenesis, plays an essential role in tumor metastasis," Cell, vol. 117, no. 7, pp. 927-939, 2004.
61. E. Casas, J. Kim, A. Bendesky, L. Ohno-Machado, C. J. Wolfe, and J. Yang, "Snail2 is an essential mediator of twist1-induced epithelial mesenchymal transition and metastasis," Cancer Research, vol. 71, no. 1, pp. 245-254, 2011.
62. F. Yang, L. Sun, Q. Li et al., "SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities," EMBO Journal, vol. 31, no. 1, pp. 110-123, 2012.
63. M.-H. Yang, D. S.-S. Hsu, H.-W. Wang et al., "Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition," Nature Cell Biology, vol. 12, no. 10, pp. 982-992, 2010.
64. N. Dave, S. Guaita-Esteruelas, S. Gutarra et al., "Functional cooperation between snail1 and twist in the regulation of ZEB1 expression during epithelial to mesenchymal transition," Journal of Biological Chemistry, vol. 286, no. 14, pp. 12024-12032, 2011.
65. U. Wellner, J. Schubert, U. C. Burk et al., "The EMT-activator ZEB1 promotes tumorigenicity by repressing stemnessinhibiting microRNAs," Nature Cell Biology, vol. 11, no. 12, pp. 1487-1495, 2009.
66. B.-T. Preca, K. Bajdak, K. Mock et al., "A self-enforcing CD44s/ZEB1 feedback loop maintains EMT and stemness properties in cancer cells," International Journal of Cancer, vol. 137, no. 11, pp. 2566-2577, 2015.
67. P. Zhang, Y. Sun, and L. Ma, "ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance," Cell Cycle, vol. 14, no. 4, pp. 481-487, 2015.
68. T. Imai, A. Horiuchi, C. Wang et al., "Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells," American Journal of Pathology, vol. 163, no. 4, pp. 1437-1447, 2003.
69. C. Sahlgren, M. V. Gustafsson, S. Jin, L. Poellinger, and U. Lendahl, "Notch signaling mediates hypoxia-induced tumor cell migration and invasion," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 17, pp. 6392-6397, 2008.
70. O. M. Martínez-Estrada, L. A. Lettice, A. Essafi et al., "Wt1 is required for cardiovascular progenitor cell formation through transcriptional control of Snail and E-cadherin," Nature Genetics, vol. 42, no. 1, pp. 89-93, 2010.
71. V. B. Sampson, J. M. David, I. Puig et al., "Wilms' tumor protein induces an epithelial-mesenchymal hybrid differentiation state in clear cell renal cell carcinoma," PLoS ONE, vol. 9, no. 7, article e102041, 2014.
72. J. Hu, H. Guo, H. Li et al., "MiR-145 regulates epithelial to mesenchymal transition of breast cancer cells by targeting Oct4," PLoS ONE, vol. 7, no. 9, Article ID e45965, 2012.
73. R. Li, J. Liang, S. Ni et al., "Amesenchymal-to-Epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts," Cell Stem Cell, vol. 7, no. 1, pp. 51-63, 2010.
74. J. Pérez-Losada, M. Sánchez-Martín, M. Pérez-Caro, P. A. Pérez-Mancera, and I. Sánchez-García, "The radioresistance biological function of the SCF/kit signaling pathway is mediated by the zinc-finger transcription factor Slug," Oncogene, vol. 22, no. 27, pp. 4205-4211, 2003.
75. B. Tanno, F. Sesti, V. Cesi et al., "Expression of slug is regulated by c-Myb and is required for invasion and bone marrow homing of cancer cells of different origin," Journal of Biological Chemistry, vol. 285, no. 38, pp. 29434-29445, 2010.
76. Y.-N. Liu, W. Abou-Kheir, J. J. Yin et al., "Critical and reciprocal regulation of KLF4 and SLUG in transforming growth factor β-initiated prostate cancer epithelial-mesenchymal transition," Molecular and Cellular Biology, vol. 32, no. 5, pp. 941-953, 2012.
77. C.-W. Li, W. Xia, L. Huo et al., "Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1," Cancer Research, vol. 72, no. 5, pp. 1290-1300, 2012.
78. K.-W. Hsu, R.-H. Hsieh, K.-H. Huang et al., "Activation of the Notch1/STAT3/Twist signaling axis promotes gastric cancer progression," Carcinogenesis, vol. 33, no. 8, pp. 1459-1467, 2012.
79. Z.-F. Chen and R. R. Behringer, "Twist is required in head mesenchyme for cranial neural tubemorphogenesis," Genes and Development, vol. 9, no. 6, pp. 686-699, 1995.
80. M.-H. Yang, M.-Z. Wu, S.-H. Chiou et al., "Direct regulation of TWIST by HIF-1α promotes metastasis," Nature Cell Biology, vol. 10, no. 3, pp. 295-305, 2008.
81. E. L. Spaeth, A. M. Labaff, B. P. Toole, A. Klopp, M. Andreeff, and F. C. Marini, "Mesenchymal CD44 expression contributes to the acquisition of an activated fibroblast phenotype via TWIST activation in the tumor microenvironment," Cancer Research, vol. 73, no. 17, pp. 5347-5359, 2013.
82. S. M. Elbashir, J. Martinez, A. Patkaniowska, W. Lendeckel, and T. Tuschl, "Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate," EMBO Journal, vol. 20, no. 23, pp. 6877-6888, 2001.
83. S.M. Elbashir, W. Lendeckel, and T. Tuschl, "RNA interference is mediated by 21- and 22-nucleotide RNAs," Genes and Development, vol. 15, no. 2, pp. 188-200, 2001.
84. G. Grelier, N. Voirin, A.-S. Ay et al., "Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype," British Journal of Cancer, vol. 101, no. 4, pp. 673-683, 2009.
85. N. H. Kim, H. S. Kim, X.-Y. Li et al., "A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition," Journal of Cell Biology, vol. 195, no. 3, pp. 417-433, 2011.
86. H. Siemens, R. Jackstadt, S. Hünten et al., "miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions," Cell Cycle, vol. 10, no. 24, pp. 4256-4271, 2011.
87. P. Bu, K.-Y. Chen, J. H. Chen et al., "A microRNA miR-34aregulated bimodal switch targets notch in colon cancer stem cells," Cell Stem Cell, vol. 12, no. 5, pp. 602-615, 2013.
88. C. Moyret-Lalle, E. Ruiz, and A. Puisieux, "Epithelial-mesenchymal transition transcription factors and miRNAs: 'Plastic surgeons' of breast cancer," World Journal of Clinical Oncology, vol. 5, no. 3, pp. 311-322, 2014.
89. R. Kumarswamy, G. Mudduluru, P. Ceppi et al., "MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer," International Journal of Cancer, vol. 130, no. 9, pp. 2044-2053, 2012.
90. S. Liu, S. M. Kumar, H. Lu et al., "MicroRNA-9 up-regulates E-cadherin through inhibition of NF-κB1-Snail1 pathway in melanoma," Journal of Pathology, vol. 226, no. 1, pp. 61-72, 2012.
91. C. Jin, B. Yan, Q. Lu, Y. Lin, and L. Ma, "The role of MALAT1/miR-1/slug axis on radioresistance in nasopharyngeal carcinoma," Tumor Biology, vol. 37, no. 3, pp. 4025-4033, 2016.
92. H. Xia, W. K. C. Cheung, S. S. Ng et al., "Loss of brain-enriched miR-124 microRNA enhances stem-like traits and invasiveness of glioma cells," Journal of Biological Chemistry, vol. 287, no. 13, pp. 9962-9971, 2012.
93. Z. Zhang, B. Zhang, W. Li et al., "Epigenetic silencing of miR-203 upregulates SNAI2 and Contributes to the invasiveness of malignant breast cancer cells," Genes and Cancer, vol. 2, no. 8, pp. 782-791, 2011.
94. F. E. Wang, C. Zhang, A. Maminishkis et al., "MicroRNA-204/211 alters epithelial physiology," FASEB Journal, vol. 24, no. 5, pp. 1552-1571, 2010.
95. M. R. Lee, J. S. Kim, and K.-S. Kim, "MiR-124a is important for migratory cell fate transition during gastrulation of human embryonic stem cells," Stem Cells, vol. 28, no. 9, pp. 1550-1559, 2010.
96. B. Li, Q. Han, Y. Zhu, Y. Yu, J. Wang, and X. Jiang, "Downregulation of miR-214 contributes to intrahepatic cholangiocarcinoma metastasis by targeting Twist," FEBS Journal, vol. 279, no. 13, pp. 2393-2398, 2012.
97. M.-L. Nairismägi, A. Vislovukh, Q. Meng et al., "Translational control of TWIST1 expression in MCF-10A cell lines recapitulating breast cancer progression," Oncogene, vol. 31, no. 47, pp. 4960-4966, 2012.
98. C.-J. Chang, C.-C. Hsu, C.-H. Chang et al., "Let-7d functions as novel regulator of epithelial-mesenchymal transition and chemoresistant property in oral cancer," Oncology Reports, vol. 26, no. 4, pp. 1003-1010, 2011.
99. E. Sánchez-Tilló, Y. Liu, O. De Barrios et al., "EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness," Cellular and Molecular Life Sciences, vol. 69, no. 20, pp. 3429-3456, 2012.
100. C. Liu, K. Kelnar, B. Liu et al., "ThemicroRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44," Nature Medicine, vol. 17, no. 2, pp. 211-216, 2011.
101. P. Trang, J. F. Wiggins, C. L. Daige et al., "Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice," Molecular Therapy, vol. 19, no. 6, pp. 1116-1122, 2011.
102. Z. Yang, S. Rayala, D. Nguyen, R. K. Vadlamudi, S. Chen, and R. Kumar, "Pak1 phosphorylation of Snail, amaster regulator of epithelial-to-mesenchyme transition, modulates Snail's subcellular localization and functions," Cancer Research, vol. 65, no. 8, pp. 3179-3184, 2005.
103. K. Zhang, E. Rodriguez-Aznar, N. Yabuta et al., "Lats2 kinase potentiates Snail1 activity by promoting nuclear retention upon phosphorylation," EMBO Journal, vol. 31, no. 1, pp. 29-43, 2012.
104. C. Du, C. Zhang, S. Hassan, M. H. U. Biswas, and K. C. Balaji, "Protein kinase D1 suppresses epithelial-to-mesenchymal transition through phosphorylation of snail," Cancer Research, vol. 70, no. 20, pp. 7810-7819, 2010.
105. B. N. Smith, L. J. Burton, V. Henderson et al., "Snail promotes epithelial mesenchymal transition in breast cancer cells in part via activation of nuclear ERK2," PLoS ONE, vol. 9, no. 8, Article ID e104987, 2014.
106. J. I. Yook, X.-Y. Li, I. Ota et al., "A Wnt-Axin2-GSK3β cascade regulates Snail1 activity in breast cancer cells," Nature Cell Biology, vol. 8, no. 12, pp. 1398-1406, 2006.
107. C. W. Li, W. Xia, S. O. Lim et al., "AKT1 inhibits epithelial-tomesenchymal transition in breast cancer through phosphorylation-dependent twist1 degradation," Cancer Research, vol. 76, no. 6, pp. 1451-1462, 2016.
108. J. Zhong, K. Ogura, Z. Wang, and H. Inuzuka, "Degradation of the transcription factor twist, an oncoprotein that promotes cancer metastasis," Discovery Medicine, vol. 15, no. 80, pp. 7-15, 2013.
109. R. Lander, T. Nasr, S. D. Ochoa, K. Nordin, M. S. Prasad, and C. Labonne, "Interactions between Twist and other core epithelial-mesenchymal transition factors are controlled by GSK3-mediated phosphorylation," Nature Communications, vol. 4, article 1542, 2013.
110. J. Hong, J. Zhou, J. Fu et al., "Phosphorylation of serine 68 of twist1 by MAPKs stabilizes twist1 protein and promotes breast cancer cell invasiveness," Cancer Research, vol. 71, no. 11, pp. 3980-3990, 2011.
111. R. Lander, K. Nordin, and C. LaBonne, "The F-box protein Ppa is a common regulator of core EMT factors Twist, Snail, Slug, and Sip1," Journal of Cell Biology, vol. 194, no. 1, pp. 17-25, 2011.
112. J. Shi, Y. Wang, L. Zeng et al., "Disrupting the interaction of BRD4 with diacetylated twist suppresses tumorigenesis in basal-like breast cancer," Cancer Cell, vol. 25, no. 2, pp. 210-225, 2014.
113. S.-P. Wang, W.-L. Wang, Y.-L. Chang et al., "p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug," Nature Cell Biology, vol. 11, no. 6, pp. 694-704, 2009.
114. H. Zheng, M. Shen, Y.-L. Zha et al., "PKD1 phosphorylation dependent degradation of SNAIL by SCF-FBXO11 regulates epithelial-mesenchymal transition and metastasis," Cancer Cell, vol. 26, no. 3, pp. 358-373, 2014.
115. M. Y. Shah and G. A. Calin, "MicroRNAs as therapeutic targets in human cancers," Wiley Interdisciplinary Reviews: RNA, vol. 5, no. 4, pp. 537-548, 2014.
116. X. Zhao, F. Pan, C.M. Holt, A.L. Lewis, and J. R. Lu, "Controlled delivery of antisense oligonucleotides: a brief review of current strategies," Expert Opinion on Drug Delivery, vol. 6, no. 7, pp. 673-686, 2009.
117. R. Garzon, G. Marcucci, and C. M. Croce, "Targeting microRNAs in cancer: rationale, strategies and challenges," Nature Reviews Drug Discovery, vol. 9, no. 10, pp. 775-789, 2010.
118. N. M. Weathington and R. K. Mallampalli, "Emerging therapies targeting the ubiquitin proteasome systemin cancer," Journal of Clinical Investigation, vol. 124, no. 1, pp. 6-12, 2014.
119. Z. J. Chen, "Ubiquitination in signaling to and activation of IKK," Immunological Reviews, vol. 246, no. 1, pp. 95-106, 2012.
120. C. H. Chan, U. Jo, A. Kohrman et al., "Posttranslational regulation of Akt in human cancer," Cell & Bioscience, vol. 4, no. 1, article 59, 2014.
121. H. Lee, C. Li, D. Ruan et al., "The DNA damage transducer RNF8 facilitates cancer chemoresistance and progression through twist activation," Molecular Cell, vol. 63, no. 6, pp. 1021-1033, 2016.
122. B. Beck, G. Lapouge, S. Rorive et al., "Different levels of Twist1 regulate skin tumor initiation, stemness, and progression," Cell Stem Cell, vol. 16, no. 1, pp. 67-79, 2015.
123. J. M. Schmidt, E. Panzilius, H. S. Bartsch et al., "Stem-celllike properties and epithelial plasticity arise as stable traits after transient twist1 activation," Cell Reports, vol. 10, no. 2, pp. 131-139, 2015.